Navigation Links
Organizational Changes at Silence Therapeutics
Date:7/17/2008

ics plc (http://www.silence-therapeutics.com)

Silence Therapeutics plc (London AIM: SLN) is a leading European RNAi focused biotechnology company. RNAi can selectively 'silence' genes linked to the onset of disease. RNAi is a Nobel Prize winning technology and one of the most promising areas of drug discovery and development today.

Silence Therapeutics has developed a platform of novel short interfering RNA ('siRNA') molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This system enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.

Silence's lead internal product, Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. Atu027 has successfully completed single and repeat dose toxicology and geno-toxicology studies, as well as a 28-day toxicology study using multiple dosing regimens. Silence plans a regulatory filing in 2008 to commence clinical trials for Atu027.

In March 2008, Silence Therapeutics announced a collaboration with AstraZeneca (LSE: AZN) focused on the development of a range of novel delivery approaches for siRNA molecules. Under the terms of the agreement both Silence Therapeutics and AstraZeneca will be allowed to commercialize the truly novel delivery systems that the two partners develop together.

In July 2007, Silence Therapeutics formed its first research and development collaboration with AstraZeneca to develop novel AtuRNAi therapeutics against five specific targets, including those in respiratory indications. This collaboration was the first industry validation of the potential application of Silence Therapeutics' pr
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Wyeth Pharmaceuticals Announces Organizational Change
2. Edwards Lifesciences Announces Organizational Changes
3. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
4. Worldwide Center for Adult Stem Cell Education LLC Changes Name to The Repair Stem Cell Institute LLC
5. Indevus Announces Management Changes
6. Molecular changes in brain fluid give insight into brain-damaging disease
7. Genmab A/S - Changes Board/Management/Auditors
8. GeneNews announces management changes to support commercialization of ColonSentry(TM)
9. Surface Logix Announces Executive Management Changes
10. China Sky One Medical, Inc. Changes Management Team
11. NYU Medical Center Changes Name to Honor Chairman of Board & Wife
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... South Korea , March 4, 2015 ... biopesticide company, in August of last year. As part ... Kyung Bon Koo continuing his role as ... , President of Vegalab S.A., will work alongside Koo ... Photo - http://photos.prnewswire.com/prnh/20150303/179218 ...
(Date:3/4/2015)... March 4, 2015 ... Paris en décembre 2011, l,étude ...   », qui compare   l es ...   sorafénib dans le carcinome hépatocellulaire avancé, a ... du foie avancé   ; les résultats sont ...
(Date:3/3/2015)... DIEGO , March 3, 2015  Halozyme Therapeutics, Inc. ... Barclays 2015 Global Healthcare Conference in Miami, FL ... a.m. PT. David A. Ramsay , Chief Financial Officer, ... be webcast through the "Investors" section of Halozyme,s corporate website ... available for 90 days following the event. To access the ...
(Date:3/3/2015)... ON , March 3, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: ... $3.7 million.  The orders are for odour control projects in ... and Asia . "Bidding activity ... , President and CEO. "After a high volume year for bidding ... into the New Year.  The recent orders reflect the organization,s renewed ...
Breaking Biology Technology:Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2
... , Trial conducted pursuant to Special Protocol ... CITY, Dec. 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... biopharmaceutical company focused on oncology and endocrine therapy, today ... ("Keryx") ( KERX), of a Phase 3 registration clinical ...
... , , SAN MARINO, Calif., Dec. 15 Epeius ... genetic medicine, gained international validation of the cutting-edge science behind ... the world rediscovered the Cyclin G1 gene to ... and thus a prime target for anti-cancer therapies. Recently, scientists ...
... , , , SAN DIEGO, Dec. 15 Aethlon Medical, Inc. ... and Dr. Wayne Comper have joined the Science Advisory ... Comper are leading researchers in the exosome field. ESI, a wholly ... discovery that the Hemopurifier®, a medical device being advanced as an ...
Cached Biology Technology:AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5
(Date:2/5/2015)... Jan. 28, 2015 Research and Markets ... of the "Global Biometrics Market (2014-2020): Market ... Countries " report to their offering. , ... Asia-Pacific is anticipated to overtake ... to increasing government spending towards IT security, government ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... The levels of contamination to water and sediment in Frenchman,s ... in some cases by as much as 250 per cent, ... of Toronto Scarborough. This is largely due to large amounts ... the study finds. Roads, parking lots and railways are ...
... Microbiology (ASM) William A. Hinton Research Training Award will ... of Biological Sciences, The University of Texas at El ... underrepresented minorities in microbiology. This award honors William A. ... African-Americans to join the ASM. Aguilera received his ...
... The ongoing El Nio of 2010 is affecting ... the West Coast fishing industry, according to scientists at ... Researchers with the California Cooperative Oceanic Fisheries Investigations ... report a stronger than normal northward movement of warm ...
Cached Biology News:Road salt and cars produce extreme water contamination in Frenchman's Bay, UTSC research reveals 2Road salt and cars produce extreme water contamination in Frenchman's Bay, UTSC research reveals 3Improved near-real-time tracking of 2010 El Niño reveals marine life reductions 2Improved near-real-time tracking of 2010 El Niño reveals marine life reductions 3
... The BioGenex VISION Sytem is ... that comes with proprietary digital imaging ... for digital image acquisition, analysis, archving/retrieval ... is a state-of-the-art digital imaging system ...
... -mr agarose is specifically for ... endoosmosis, and is recommended for ... weight proteins or complexes that ... of molecular sieving in polyacrylamide ...
... is used for second-dimension SDS-PAGE sample ... place in PROTEAN Plus cells. Bromophenol ... allow monitoring of electrophoresis runs. The ... in 1x Tris, glycine, SDS, and ...
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
Biology Products: